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Abstract 
Background 
Type 2 diabetes is an established risk factor for the presence and progression of fatty liver.  
Little is known about the distributions and correlates of hepatic non-invasive biomarkers in 
community based populations with diabetes, unselected for liver disease. 
Aims 
We aimed to identify the distribution of, and metabolic risk factors associated with serum 
cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, 
representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, 
ET2DS). 
Methods 
939 ET2DS participants, aged 60-74 years underwent physical examination including 
ultrasound for assessment of liver fat.  Representative subgroups were assessed for markers 
of chronic liver disease (CK18 and ELF). 
Results 
CK18 values ranged from 29-993 U/L (median 102, IQR 76-137 U/L) and ELF scores ranged 
from 6.9-11.6 (mean 8.9, SD 0.8). Statistically significant associations were found between 
both biomarkers and a number of metabolic risk factors. Neither CK18 nor ELF was 
consistently or strongly associated with established hepatic risk factors (alcohol excess, 
hepatotoxic medication use and positive immunology titres).   
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Conclusions 
We identified the distribution of CK18 and ELF in a large cohort of older people with type 2 
diabetes and showed that these markers are associated with an adverse metabolic risk factor 
profile, although much of the variation in biomarkers remained unexplained.  Prospective 
studies are required to determine the extent to which CK18 and/or ELF predict the 
development of symptomatic liver disease and to identify additional risk factors which may 
influence the development of advanced liver disease in people with type 2 diabetes.   
Keywords 
Non-invasive hepatic biomarkers, cytokeratin-18, Enhanced Liver Fibrosis score, fatty liver 
disease, type 2 diabetes mellitus 
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Introduction 
Type 2 diabetes is an established risk factor for fatty liver in Western countries(1). The 
commonest cause of fatty liver, non-alcoholic fatty liver disease (NAFLD), ranges from 
simple steatosis (non-alcoholic fatty liver, NAFL), through to liver inflammation (non-
alcoholic steatohepatitis, NASH) and on to NASH with liver scarring (fibrosis) and cirrhosis 
(end stage fibrosis).  The consequences of the more advanced stages of NAFLD, including 
cirrhosis, liver failure and hepatocellular carcinoma (2) are becoming increasingly common;  
NAFLD is the third most frequent indication for liver transplantation in the USA and 
transplants performed with NAFLD as the primary aetiology rose from 1.0% in 2001 to 8.5% 
in 2009(3).  Even without transplant, NASH and advanced stages of liver disease are 
associated with higher individual healthcare costs (4).  In type 2 diabetes, significant 
mortality related to chronic liver disease (CLD) has been reported(5) with a standardised 
mortality ratio (SMR) of 2.52 for liver cirrhosis compared with the general population in a 
European cohort (compared with a SMR for cardiovascular disease of 1.34)(6).   
Given the potential burden caused by symptomatic (advanced) liver disease in the diabetic 
general population, there is a need to investigate potential methods of identifying 
asymptomatic stages of the condition in adults with diabetes, as indeed is the case for other 
high risk sub-groups within the general population.  Liver biopsy, which to date has been the 
mainstay of liver fibrosis diagnosis, has limited usefulness in the investigation of large groups 
of people from healthy populations (i.e. those unselected for  liver disease) because of its 
invasive nature, complication rates(7), sampling errors(8) and inter-observer variability(8). 
Therefore, interest is increasing in the use of non-invasive biomarkers of liver inflammation 
and fibrosis which might be useful in the identification of particularly high risk groups of 
individuals. 
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In the current study, we sought to determine the distribution, and factors influencing levels 
of, two promising non-invasive liver markers, serum cytokeratin-18 (CK18) and the 
Enhanced Liver Fibrosis (ELF) score.  These markers have previously been validated for 
hepatic inflammation and fibrosis respectively against liver biopsy in  patients with 
established chronic liver disease attending tertiary care settings. CK18, a caspase cleaved 
fragment released by injured hepatocytes and  a measure of hepatic cell damage such as  
inflammation in NASH,  is raised in patients with CLD compared with people without CLD 
(9) and can differentiate between steatosis and NASH(10-12)in patients with NAFLD (14-
16).  ELF uses an extra-cellular matrix panel (hyaluronic acid (HA), N-terminal pro-peptide 
of collagen type III (P3NP) and tissue inhibitor of metalloproteinase-1 (TIMP-1) to quantify 
fibrosis and has been validated for use in patients with NAFLD(13) with increasing accuracy 
for severe fibrosis detection compared to earlier stages. However, neither biomarker has been 
validated in general population-based cohorts, nor in diabetic populations, an important issue 
which has been hampered to date by lack of information on their distribution and clinical 
correlates in such populations. 
A recent study in South Korea reported on the normal distribution of ELF in adults without 
known CLD(14).  This unique study of a large group of patients with type 2 diabetes, 
unselected for liver disease; investigates the distribution and clinical correlates of non-
invasive markers of liver fibrosis and inflammation. Adding to previous studies which have 
focussed on hospital outpatient settings and the use of liver biopsy(15, 16). Such information 
is necessary for the purpose of screening and treatment of undiagnosed liver disease in 
diabetic patients and also to underpin further research into the causes and consequences of 
asymptomatic liver disease in adults with diabetes. 
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Patients and Methods 
The Edinburgh Type 2 Diabetes Study 
Recruitment and examination of ET2DS subjects have been published elsewhere(17).  In 
brief, 1066 men and women aged 60 to 75 years were recruited at random from the Lothian 
Diabetes Register.  ET2DS participants have been shown previously to be representative of 
all those randomly selected to participate in the study (n=5454), and of the target population 
of older people with type 2 diabetes living in the general population(18). One year after 
recruitment and baseline examination, 939 participants (88%) returned for further clinical and 
liver assessment (19, 20). Subjects returning at year 1 were similar to the full ET2DS 
population in terms of a number of variables including demographics, body fat measures, 
glucose and HbA1c measures, lipid profiles, blood pressure and medication use(18, 19). 
Clinical examination 
Clinical examination included a fasting blood sample for measurement of plasma glucose, 
HbA1c, total cholesterol, triglycerides, estimated glomerular filtration rate (eGFR), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase and 
platelets; measurement of height, weight, and waist circumferences; a self-administered 
questionnaire including questions on year of diabetes diagnosis, current medications, alcohol 
consumption, history of joint and liver disease.  In addition, patients underwent abdominal 
ultrasound scan (USS) and those participants with evidence of hepatic steatosis or plasma 
liver enzymes above the laboratory reference limits received a ‘liver screen’ including: 
hepatitis B virus serology, hepatitis C virus serology, alfa-fetoprotein, ferritin and 
autoantibodies (anti-nuclear antibody (ANA), anti-mitochondrial antibody (AMA) and anti-
smooth muscle antibody (ASmA))(19).  CK18 and ELF were measured in stored serum 
samples (-80C), taken at the time of the liver USS.   
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Average alcohol intake per week over the previous year and history of alcohol excess were 
determined from  two questions in the self-completion questionnaire, adapted from the 
AUDIT-C screening tool(21): “How often did you have a drink containing alcohol in the past 
year?”(a drink was considered to be one and a half alcohol units); and “How many drinks did 
you have on a typical day when you were drinking in the last year?”. Self-reported data on 
potential hepatotoxic medication use within the previous 6 months were confirmed by review 
of medical records.  
Identifying pre-diagnosed liver disease 
The presence of liver disease diagnosed prior to attendance at the research clinic was 
identified from data linkage to SMR01 general and acute inpatient discharge records (at NHS 
National Services Scotland, Information Services Division) and from questions on prior 
health condition in the  patient  questionnaires. Diagnoses were verified by review of medical 
records. Patients with confirmed chronic viral hepatitis, haemochromatosis and primary 
biliary cirrhosis were excluded from the final analyses as biomarkers are known to perform 
differently in these conditions. 
Defining hepatic steatosis 
Hepatic steatosis was determined by abdominal USS as described previously(22). The same 
sonographer, blinded to the participants’ clinical history, undertook all scanning and grading. 
The liver was graded for markers of hepatic steatosis using established criteria: bright hepatic 
echo pattern (when compared to the right kidney), increased attenuation of the echo beam 
(visualised as poor imaging of the diaphragm or intrahepatic vessels) and the presence of 
focal fatty sparing.(19, 23-25). In a subset, sonographic steatosis was validated using 
magnetic resonance spectroscopy with an optimal fat fraction cut-off of 6%(22) following 
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which grades were defined as: normal (fat fraction <6.1%) or significant steatosis (fat fraction 
>6%). Radiological signs of cirrhosis were also noted and spleen size was measured in cm. 
Laboratory Measurements 
CK18 was measured using the M30-Apoptosense® ELISA (PEVIVA AB, Stockholm, 
Sweden) at the Biomedical Research Unit laboratory (University of Nottingham, UK) and 
ELF using the ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics Inc, 
New York, USA) at the iQur laboratory (London, UK). The individual ELF markers are 
combined using the algorithm 
ELF=2.588+(ln(HA)*0.681)+(ln(P3NP)*0.775)+(ln(TIMP1)*0.494)(13). All other 
biochemical variables were analysed using a Vitros Fusion chemistry system (Ortho Clinical 
Diagnostics, Bucks, UK) at the Western General Hospital (Edinburgh, UK). AST/ALT ratio 
was calculated as AST(U/L)/ALT(U/L) and the aspartate to platelet ratio index (APRI) was 
calculated as [[AST(U/L)/upper limit normal]/platelets(x10
9
/L)]*100. 
Data Analysis 
Data were analysed using SPSS v19.0 (SPSS Inc., Illinois, USA). Alcohol excess was defined 
according to established criteria as alcohol intake >14 units/week (female) or >21 units/week 
(male)(26), or participant self-report of current/previous alcohol excess(2). Use of 
hepatotoxic medication included the use of (non-topical) glucocorticoids for >2 weeks, 
isoniazid, methotrexate, amiodarone, or tamoxifen within the 6 months prior to USS(2, 27). 
Clinically significant positive immunology titres were defined as ASmA titre >1:160 or 
AMA titre >1:40(2, 28). CKD was defined as eGFR<60 mls/min/1.73m
2
. Patients were 
considered to have arthritis if they reported a history of osteoarthritis, rheumatoid arthritis, 
scleroderma or any other joint disease. Continuous variables were assessed for normality with 
CK18, duration of diabetes and triglycerides requiring transformation for analysis. 
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The associations of CK18 and ELF with the following were examined, (i) duration of 
diabetes and diabetes treatment categorised as diet-controlled, oral anti-hypoglycaemic agents 
(OAHA) only or insulin +/- OAHA,), (ii) metabolic variables (total cholesterol, triglycerides, 
fasting glucose, HbA1c, BMI calculated as weight (kg)/height (m)
2
 and waist circumference), 
(iii) steatosis on USS and, (iv) established risk factors for CLD (alcohol excess, hepatotoxic 
medication, positive immunology). The influence of CKD and arthritis (on circulating 
biomarker level) was assessed by analysing their prevalence in the highest and lowest 
quintiles of each biomarker. Analyses were undertaken on (i) all subjects, (ii) subjects with 
steatosis (defined as the presence of steatosis on USS) and, (iii) subjects with NAFL (defined 
as the presence of steatosis on ultrasound without alcohol excess, use of hepatotoxic 
medication or raised autoantibodies).  
Univariate analysis of potential risk factors was undertaken using Pearson’s correlation and 
ANOVA adjusting for age and sex. Multivariate analysis was undertaken using linear 
regression both unadjusted and fully adjusted for age, sex, and established hepatic risk 
factors.  
A sensitivity analysis addressing missing CK18 and ELF data was performed using multiple 
imputation by chained equations(29). Data were considered to be missing completely at 
random as they were missing due to technical problems or insufficient stored sample.  
Ethical approval was obtained from the Lothian Research Ethics Committee and all subjects 
gave written informed consent. 
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Results 
Subject characteristics  
Of the 939 ET2DS participants who underwent liver ultrasound and further physical and liver 
assessment, 899 did not have pre-diagnosed liver disease or CLD on screening and were 
considered for inclusion in the current analysis (15 subjects were excluded due to pre-
diagnosed CLD, a further 3 due to CLD on screening and 22 because they did not have a liver 
screen when indicated). 825 and 568 of these subjects underwent measurement of CK18 and 
ELF respectively and form the primary study populations for this paper.  A number of ELF 
measurements were missing due to inadequate sample volumes. Details of the flow of 
patients through the study are shown in figure 1 and characteristics of the study populations 
are described in table 1.  Compared with all subjects undergoing ultrasound examination, the 
populations with CK18 and ELF data available had similar clinical and metabolic 
characteristics.  Prevalence of steatosis was 56.8% and the prevalence of NAFL (defined as 
the presence of steatosis on ultrasound without alcohol excess, use of hepatotoxic medication 
or raised autoantibodies) 31.5%. 
Biomarker distributions  
CK18 values ranged from 29 to 993 U/L (median 102, IQR 76-137 U/L) and ELF scores 
ranged from 6.9 to 11.6 (mean 8.9, SD 0.8). Distributions of CK18 were similar in men and 
women (medians 104 vs 100 respectively, p>0.05) with ELF scores slightly lower in men 
(means 8.8, SD 0.7 and 9.0, SD 0.8, respectively, p=0.016).  ELF, but not CK18, increased 
significantly with age (r=0.28, p<0.001 and r=-0.08, p>0.05 respectively) and the two 
markers significantly, though relatively weakly, correlated with each other (r=0.13, p=0.002). 
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Association of CK18 and ELF with hepatic steatosis and established hepatic 
risk factors 
Subjects with hepatic steatosis (n=460) had higher CK18 values compared with those without 
steatosis (n=365) (medians 120.2 vs 87.7U/L respectively, p<0.001).  The opposite was found 
for patients with NAFL (medians 87.4 vs 112.5 U/L, p<0.001). ELF scores were similar in 
participants with steatosis (n=319) compared with those without steatosis (n=259) (means 
8.88 vs 8.90, p>0.05), with similar results for the presence of NAFL (means 8.95 vs 8.87, 
p>0.05).   
The associations of CK18 with established hepatic risk factors  (excess alcohol intake, 
positive immunology titres and hepatotoxic medication use) are shown in Table 2a, for all 
subjects (n=825) and for those with steatosis (n=460).  After adjustment for age and sex, 
mean CK18 was significantly higher in subjects reporting excess alcohol intake but 
differences in positive immunology titres and hepatotoxic medication use were not 
statistically significant.  
Similar findings for ELF are presented in table 2b, again for all subjects (n=568) and for 
those with steatosis (n=319).  ELF appeared, if anything, slightly lower in subjects with 
established risk factors for liver dysfunction, but differences were not statistically significant.   
Association of CK-18 and ELF with metabolic risk factors 
Age and sex adjusted associations of CK18 and ELF with metabolic variables are shown in 
Table 2. Higher CK18 levels were significantly associated with hyperglycaemia, increased 
body fat (higher BMI and waist circumference) and with higher serum triglyceride levels.  
Only the association with waist circumference remained statistically significant when 
analyses were restricted to subjects with NAFL. 
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Higher ELF levels were significantly associated with increasing duration of diabetes, with 
hyperglycaemia and with increased body fat. Compared with subjects who were treated with 
diet alone, mean ELF was significantly higher in subjects using OAHA alone (means 8.9 vs 
8.7, p=0.012) and in those using insulin (mean 9.2 vs 8.7, p<0.001).  The associations with 
ELF changed little when analyses were restricted to only subjects with steatosis or NAFL.  
Characteristics of subjects in highest CK-18 and ELF quintiles 
Since particularly high levels of CK18 and ELF may be diagnostic of clinically important 
liver inflammation and fibrosis respectively, we determined the clinical characteristics of 
subjects in the top biomarker quintiles (Table 3).   
Compared with subjects in the bottom four quintiles, subjects in the highest CK18 quintile 
had significantly higher indices of hyperglycaemia, higher triglyceride levels and increased 
body fat.  In addition, more were on intensive diabetes treatment (including insulin) and more 
reported drinking excess alcohol.  When analyses were restricted to subjects with NAFL, no 
statistically significant differences were found (data not shown). 
Subjects in the highest ELF quintile were slightly older, had longer diabetes duration and 
were more likely to require insulin therapy. These statistically significant differences 
persisted when the analyses were restricted to subjects with NAFL (age: mean 69.4 vs 67.8 
yrs,  p=0.010; duration of diabetes: 6.97 vs 6.74 years, p=0.010, on insulin therapy: 27.5 vs 
13.5%, p=0.021). 
Subjects were also assessed for surrogate markers of advanced fibrosis. Subjects in the top 
ELF quintile had significantly higher mean spleen size (10.6 vs 10.1cm, p=0.020), APRI 
(0.34 vs 0.26, p<0.001), AST/ALT ratio (1.02 vs 0.93, p=0.011) and lower platelet count 
(246 vs 267 x10
9
/L, p=0.005). 
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Liver biomarkers were not significantly associated with other conditions known to potentially 
affect their levels in the circulation. The top and lower CK18 quintiles had similar 
proportions of subjects with CKD (19.4% vs 18.3%, p=0.74) and the top and lower ELF 
quintiles had similar proportions of individuals with a diagnosis of arthritis (41.6% vs 38.0%, 
p>0.05). 
Multivariate analysis 
In multivariate models adjusting for age, sex and established hepatic risk factors (Table 4), 
statistically significant positive predictors of CK18 were presence of hepatic steatosis, serum 
triglycerides and measures of increased body fat, hyperglycaemia and more intensive diabetes 
treatment.  Similar predictors for ELF were duration of diabetes, more intensive diabetes 
treatment and body fat.  In these models, r
2
 ranged from 2.6 to 10.1% for risk factors 
influencing CK18 and from 12.7 to 13.7% for risk factors influencing ELF.  
Due to the relatively large number of subjects in whom ELF (and to a lesser extent, CK18) 
data were unavailable (i.e. ‘missing’ at random), a sensitivity analysis was undertaken using 
multiple imputation (imputation dataset included all 899 subjects eligible for inclusion in the 
analyses - see figure 1). The results confirmed those in the original dataset with only minimal 
differences found in effect sizes and significance levels (data available on request). 
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Discussion 
The strength of this study is the comprehensive assessment of CK18 and ELF in a 
population-based cohort of all older people with type 2 diabetes, and not just subjects 
selected primarily on the diagnosis of steatosis of the liver using recruitment from diabetes 
clinics at tertiary referral centres as in previous studies(15, 30-32).  We have provided 
diabetes-specific information on the distribution of these biomarkers, which is essential to 
inform further research on the clinical relevance of possible subclinical liver dysfunction in 
this high risk group.   We also demonstrated that higher CK18 levels were associated with 
hepatic steatosis, excess alcohol intake, increased body fat, higher serum triglyceride and 
circulating glucose levels. ELF scores increased with age and duration of diabetes and were 
associated with increased body fat and more intensive diabetes treatment. A challenge in 
interpreting these results clinically is the lack of validated biomarker cut-points to diagnose 
hepatic inflammation and/or fibrosis in population-based cohorts.  Despite this, our results 
suggest that at least a number of metabolic risk factors are likely to be associated with liver 
fibrosis and/or inflammation in people with type 2 diabetes.   
Whilst accepted as imperfect, especially in NAFLD (8), liver biopsy remains the gold 
standard for staging liver disease, but biopsy is not acceptable in  large studies of 
asymptomatic participants. Cut-points for the non-invasive biomarkers used in the current 
study have been well validated for staging liver disease in secondary care patient populations 
with an intrinsically higher prevalence of CLD, including NAFLD, but have not been 
validated as a diagnostic tool in either general population groups or in patients with type 2 
diabetes. Given the considerable influence of disease prevalence on the predictive values of 
diagnostic tests, the results from hospital-based studies could not be transferred to our own 
community-based, ‘low prevalence’ population without resulting in an unacceptably high 
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number of false positive and negative results. In terms of diabetic populations, it is not known 
whether ELF scores differ, on average, from non-diabetic populations, although there is also 
no known biological reason why this should be the case.  For these reasons, we chose the top 
quintile of the biomarker distribution as our highest risk groups.  Whilst the imprecision of 
such an approach in terms of diagnosing disease must be acknowledged, we have shown that 
the highest ELF quintile contained higher surrogate markers of advanced fibrosis, providing 
some confirmatory evidence that, at least for ELF, this group included a particularly high risk 
group of patients in terms of advanced liver disease.  In addition we were able to confirm that 
the presence of other conditions known to influence levels of the biomarkers do not appear to 
have a major effect on the results.  
In terms of the distributions of potential inflammation and fibrosis biomarkers, our findings 
for CK18 were consistent with the assay literature(33).  In developing the normal ranges for 
the serum CK18 assay, 200 ‘healthy’ Swedish blood donors were tested; as in our study, the 
results showed similar levels in males and female with little change in levels with increasing 
age and an overall biomarker distribution similar to the one we found.  In one study (33),  a 
normal cut-point of the 80
th
 percentile, or 145U/L, was suggested, and this is also consistent 
with our finding (146U/L).  There is minimal literature examining ELF distributions in 
individuals unselected for liver disease. Yoo et al suggest a normal range of 5.95-8.73 in 
South Korean subjects without known CLD(14). We found that ELF scores were very 
slightly lower in men and increased with age.  In the absence of a  biologically plausible 
reason to expect any difference in any of the components of ELF by sex, it is possible that the 
higher ELF scores in females may truly represent more advanced liver disease. The 
components of ELF (HA, TIMP-1 and P3NP) are all related to extra-cellular matrix turnover 
and are not exclusive to the liver.  As a result, one might expect an increase in ELF with age, 
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both due to the greater time in which liver fibrosis has had to develop(34) and due to 
increasing prevalence of unrelated causes of raised analytes and indeed, consistent with our 
own findings, an early study examining HA and P3NP found higher levels in ‘healthy’ 
elderly people compared with younger participants (35) . 
Our finding of associations of hepatic steatosis, raised serum triglycerides and increased body 
fat, hyperglycaemia and more intensive diabetes treatment with CK18, and of duration of 
diabetes, more intensive diabetes treatment and body fat with ELF, support the possibility 
that poor diabetes control and a worse metabolic profile may be increasing the risk of 
developing CLD.  Our findings contrast those of a recent liver biopsy study (15) in people 
with type 2 diabetes, in which high rates of both NASH (78%) and moderate fibrosis (34-
60%) were detected, but which did not find associations between diabetes related/metabolic 
factors and NASH or liver fibrosis.  However, this biopsy study was small (n=98) and 
focused on patients at the severe end of the diabetes spectrum attending a tertiary referral 
hospital. 
The cross-sectional nature of our study limits any temporal inference; it is not possible to 
determine whether metabolic factors are a risk factor for liver disease or vice versa.  
However, if causal relationships were to be confirmed,  this would have important 
implications for strategies aimed at CLD risk reduction e.g. losing/redistributing fat and 
reducing insulin resistance. Although associations between the biomarkers and metabolic 
factors appeared relatively weak, addressing even weak risk factors for disease could be 
beneficial at a population level, especially if those risk factors are highly prevalent. 
In addition to the association of CK18 and ELF with metabolic risk factors, we were also 
interested in their association with steatosis and established hepatic risk factors. We found 
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that subjects with hepatic steatosis had higher CK18 levels, but not ELF, compared with non-
steatotic individuals. This is perhaps unsurprising given that CK18 levels rise with increasing 
hepatic inflammation as a by-product of hepatocellular apoptosis and that according to 
established models of NAFLD progression(27, 36), initial development of hepatic steatosis is 
followed by NASH and then hepatic scarring with steatosis typically receding as fibrosis 
progresses.  Conversely, patients fulfilling the criteria for NAFL had significantly lower 
levels. This suggests that the alternative causes of steatosis (hepatotoxic medications, alcohol 
and strongly positive autoantibody titres) are driving the inflammatory element, with those 
patients with NAFL having a more benign course. We found little evidence of a strong 
association between hepatic risk factors and either CK18 or ELF.   Lack of associations may 
be explained, at least in part, by the small numbers of study participants with high levels of 
the hepatic risk factors and by lack of consensus around the precise level of risk factor which 
should be used to establish increased risk.  We defined alcohol excess using cut-points which 
are consistent with the published literature in the UK, only six participants had positive 
autoantibodies and we were unable to find any consensus in the literature on how best to 
define hepatotoxic medications in terms of what types, duration and dosage are required to 
have a significant effect on the liver(2).  
One of the most consistent findings in the current study was the association of both 
biomarkers with measures of increasing body fat.  Previous studies have shown a direct 
association between liver fat and  hepatic inflammation, with the latter increasing 
proportionately according to liver fat volume(37). It has been proposed that this effect is  
mediated though the direct release of toxic free fatty acid by hepatic fat and through altered 
lipid partitioning within hepatocytes, mitochondrial dysregulation, generation of reactive 
oxygen species, lipid peroxidation and endoplasmic reticulum stress(38). Given the 
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relationship between visceral fat and inflammation, our finding of increased body fat in 
patients in the highest CK18 quintile is consistent with proposed underlying mechanisms of 
hepatic inflammation(39, 40).  In addition to increased body fat, subjects in the top CK18 
quintile also had higher fasting glucose and plasma HbA1c levels, as well as more intensive 
diabetes treatment modalities.  These factors may  be considered  as surrogates of beta cell 
failure and worsening insulin resistance, which is in turn related to hepatic inflammation 
through increased lipolysis, increased free fatty acid presence in the liver and ultimately 
oxidative stress(41). As in other studies (42, 43), we found higher triglyceride levels with 
increased CK18 levels, which would be consistent with  the theory of free fatty acids driving 
lipid accumulation in the form of triglycerides in the liver in NAFL. 
In conclusion, we have provided important new information on the distribution of CK18 and 
ELF in an elderly diabetic population unselected for liver disease.  Also, we have provided 
evidence that CK18 and ELF are increased in those people with type 2 diabetes who have a 
more adverse metabolic profile, including higher levels of body fat, whilst established risk 
factors for CLD were not found to have a major influence of levels of the biomarkers.  These 
findings could help identify particularly high risk groups within the diabetic population who 
may benefit from increased surveillance in relation to development of CLD and/or from 
targeting of specific metabolic risk factors.  Prospective studies are now required to 
determine the extent to which CK18 and/or ELF predict the development of symptomatic 
liver disease and to identify additional risk factors responsible for the development of 
advanced liver disease in people with type 2 diabetes. 
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a
 Pre-diagnosed liver diseases (n=15) included alcohol related liver disease (n=7), autoimmune 
hepatitis (n=2), primary biliary cirrhosis (n=2), haemochromatosis (n=1), granulomatous hepatitis 
(n=1), chronic cholangitis (n=1) and carcinoid tumour (n=1). 
b
 Screen-detected liver disease included hepatitis B virus n=1, hepatitis C virus n=1, hepatocellular 
carcinoma n=1 
c Missing data values due to inadequate sample volumes. 
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Table 1. Characteristics
a
 of all ET2DS participants undergoing liver assessment (n=939) 
and groups with CK18 (n=825) and ELF (n=568) measurements. Values are mean 
(SD)/median (IQR) or proportion (n) 
 All participants 
n=939 
CK18 participants 
n=825 
ELF participants 
n=568 
Age, years 68.9 (4.2) 68.8 (4.2) 68.7 (4.2) 
Sex, % male 52.0 (488) 53.6 (442) 49.8 (283) 
    
Duration of diabetes, years 7.0 (4.0-12.0) 7. (4.0-12.0) 7.0 (4.0-11.0) 
HbA1c, % 7.19 (1.1) 7.19 (1.0) 7.20 (1.0) 
HbA1c, mmol/mol 55.1 (11.7) 55.0 (11.4) 55.1 (12.3) 
Fasting glucose, mmol/l 6.87 (2.3) 6.92 (2.3) 6.90 (2.3) 
Diet controlled, % yes 19.4 (182) 19.8 (163) 18.8 (107) 
OAHA use, % yes 64.9 (609) 65.3 (539) 66.7 (379) 
Insulin therapy, % yes 15.8 (148) 14.9 (123) 14.4 (82) 
    
BMI, kg/m2 31.3 (5.7) 31.2 (5.6) 31.2 (5.7) 
Waist circumference, cm 106.7 (12.8) 106.7 (12.7) 106.3 (12.5) 
Serum total cholesterol, mmol/L 4.14 (0.8) 4.15 (0.8) 4.15 (0.8) 
Systolic BP, mmHg 138.1 (18.5) 138.1 (18.2) 138.5 (18.1) 
Diastolic BP, mmHg 74.1 (9.6) 74.4 (9.1) 74.6 (8.9) 
    
Hepatic steatosis, % yes 56.8 (533) 55.8 (460) 56.2 (319) 
NAFLDb, % yes 31.5 (296) 32.4 (267) 31.5 (179) 
    
Alcohol, units/week 1..3 (0-10.1) 2.3 (0-10.1) 0.6 (0-10.1) 
Alcohol excess, % yes 12.2 (114) 11.8 (97) 12.4 (70) 
Current smoker, % yes 13.0 (122) 13.1 (108) 12.7 (107) 
a
 All variables were measured concurrently at year 1 examination of the ET2DS, except for BMI and waist 
circumference which were measured at baseline. 
b
 Defined as the presence of steatosis on ultrasound without alcohol excess, use of hepatotoxic medication or 
raised autoantibodies  
c
 Defined as females >14 units/week, males >21 units/week or patient disclosed history of a current or prior 
alcohol problem. 
HbA1c, glycosylated haemoglobin; OAHA, oral anti-hyperglycaemic agent 
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Table 2a. Association of CK18 with metabolic and established hepatic risk factors. 
Values are age and sex adjusted correlation coefficients or mean (SEM) 
 All patients with CK18a 
available n=825 
Patients with steatosis 
n=460 
Patients with NAFLD 
n=378 
       
Duration of diabetesa, years 0.015 NS 0.043 NS 0.037 NS 
Treatment type          Diet controlled 100.5 (1.8)  111.2 (3.0)  112.2 (3.4) NS 
          OAHA useb 109.7 (1.1) NS 127.4 (1.8) NS 123.3 (1.8) NS 
          Insulin therapyb 113.0 (2.4) NS 136.8 (4.1) 0.026 126.2 (4.0) NS 
Metabolic risk factors 
Fasting glucose, mmol/L 0.093 0.008 0.112 0.016 0.062 NS 
HbA1c, % and mmol/mol 0.064 NS 0.070 NS 0.048 NS 
Body mass index, kg/m2 0.117 <0.001 0.032 NS 0.085 NS 
Waist circumference, cm 0.138 <0.001 0.061 NS 0.116 0.024 
Serum total cholesterol, mmol/L -0.051 NS -0.041 NS -0.073 NS 
Serum triglyceridesa, mmol/L 0.142 0.001 0.064 NS 0.100 NS 
Established hepatic risk factors 
Excess alcohol intakec             Yes 125.6 (3.0)  146.9 (4.7)   
                                                   No 106.2 (1.0) 0.004 122.7 (1.5) 0.002 
Positive immunologyd                                                                         Yes 120.5 (11.3)  97.5 (17.7)  
                                                   No 110.2 (0.9) NS 125.6 (1.4) NS 
Hepatotoxic medication usee       Yes 121.1 (5.1)  143.2 (7.6)  
                                                   No 107.9 (0.9) NS 124.7 (1.5) NS 
 
Table 2b. Association of ELF with markers of diabetes, the metabolic syndrome and 
liver dysfunction at year 1. Values are age and sex adjusted correlation coefficients or 
mean (SEM) 
 All patients with ELF 
available n=568 
Patients with steatosis 
n=319 
Patients with NAFLD 
n=259 
       
Duration of diabetesa, years 0.138 0.001 0.181 0.001 0.167 0.008 
Treatment type          Diet controlled 8.71 (0.07)  8.68 (0.10)  8.73 (0.11)  
          OAHA usea 8.91 (0.04) 0.012 8.86 (0.05) NS 8.89 (0.05) NS 
          Insulin therapya 9.15 (0.08) <0.001 9.21 (0.10) <0.001 9.23 (0.11) 0.002 
Metabolic risk factors 
Fasting glucose, mmol/L 0.048 NS 0.025 NS -0.006 NS 
HbA1c, % and mmol/mol 0.090 0.033 0.048 NS 0.074 NS 
Body mass index, kg/m2 0.170 <0.001 0.237 <0.001 0.252 <0.001 
Waist circumference, cm 0.148 <0.001 0.175 0.002 0.192 0.002 
Serum total cholesterol, mmol/L -0.035 NS -0.089 NS -0.068 NS 
Serum triglycerides*, mmol/L -0.008 NS -0.116 NS -0.140 NS 
Established hepatic risk factors 
Excess alcohol intakeb             Yes 8.74 (0.09)  8.69 (0.11)   
                                                   No 8.93 (0.03) NS 8.91 (0.04) NS 
Positive immunologyc                                                                  Yes 8.61 (0.30)  8.31 (0.50)  
                                                   No 8.90 (0.03) NS 8.89 (0.04) NS 
Hepatotoxic medication used       Yes 8.85 (0.17)  8.77 (0.20)  
                                                   No 8.91 (0.03) NS 8.89 0.04) NS 
a 
Analysed on the Log10 scale 
b 
vs diet controlled 
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c
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior 
alcohol problem. 
d 
Defined as ASmA titer >1:160 or AMA titer >1:40 
e 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic. 
Continuous variables analysed using Pearson’s correlation, categorical variables analysed using univariate 
analysis of variance.  
CK18, cytokeratin-18; HbA1c, glycosylated haemoglobin; OAHA, oral anti-hyperglycaemic agent; SEM, 
standard error of the mean. 
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Table 3. Risk factors in highest versus lower quintiles of CK18 and ELF. Values are 
mean (SEM) or proportion (%) 
 
CK18 
Quintile 1-4 
n=660 
(<146.6 U/L) 
CK18  
Quintile 5  
n=165 
(≥146.6 U/L) 
p 
 ELF  
Quintile 1-4  
n=455 
(score <9.5) 
ELF  
Quintile 5  
n=113  
(score ≥9.5) 
p 
Demographics 
Age 69.0 (0.16) 68.2 (4.6) NS  68.3 (0.19) 70.6 (0.37) <0.001 
Sex, % male 54.5% (360) 49.7% (82) NS  51.4% (234) 43.4% (49) NS 
 
Duration of diabetesa, years 7.04 (0.08) 7.29 (0.16) NS  6.75 (0.09) 7.93 (0.26) 0.028 
Treatment type  Diet controlled 22.0% (145) 10.9% (18) 0.001  20.2% (92) 13.3% (15) NS 
OAHA use 72.6% (479) 83.6% (138) 0.004  75.8% (307) 79.6% (90) NS 
Insulin therapy 13.9% (92) 18.8% (31) NS  12.3% (56) 23.0% (26) 0.007 
Metabolic risk factors 
Fasting glucose, mmol/L 6.80 (0.09) 7.36 (0.19) 0.008  6.86 (0.10) 7.07 (0.25) NS 
HbA1c, % 7.14 (0.04) 7.36 (0.08) 
0.013 
 7.19 (0.05) 7.22 (0.10) 
NS 
HbA1c, mmol/mol 54.5 (0.44) 57.0 (0.91)  55.1 (0.53) 55.4 (1.09) 
Body mass index, kg/m2 31.0 (0.22) 32.3 (0.45) 0.009  31.0 (0.26) 31.8 (0.55) NS 
Waist circumference, cm 106.2 (0.50) 108.7 (0.97) 0.020  105.9 (0.58) 107.7 (1.22) NS 
Total cholesterol, mmol/L 4.15 (0.04) 4.13 (0.07) NS  4.17 (0.04) 4.09 (0.09) NS 
Triglycerides*, mmol/L 1.42 (0.01) 1.68 (0.03) 0.001  1.44 (0.02) 1.52 (0.03) NS 
USS detected hepatic steatosis 
Steatosis  49.4% (326) 81.2% (134) <0.001  56.9% (259) 53.1% (60) NS 
Established hepatic risk factors 
Excess alcohol intakeb                   10.3% (68) 17.6% (29) 0.014  13.4% (61) 8.0% (9) NS 
Positive immunology titresc        0.7% (4) 1.2% (2) NS  1.4% (6) 0% (0) NS 
Hepatotoxic medication used   3.5% (23) 4.2% (7) NS  3.5% (16) 2.7% (3) NS 
a 
Analysed on the Log10 scale 
b
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior 
alcohol problem. 
c 
Defined as ASmA titer >1:160 or AMA titer >1:40 
d 
Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the year 1 clinic. 
e
 Defined as eGFR<60 mls/min/1.73m2 
Continuous variables analysed using Students t-test, categorical variables analysed using Chi-square.  
CKD Chronic kidney disease; CK18, cytokeratin-18; ELF, European Liver Fibrosis panel; HbA1c, glycosylated 
haemoglobin; OAHA, oral anti-hyperglycaemic agent; SEM, standard error of the mean.
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Table 4. Multivariate association of risk factors with CK18 and ELF. Values are 
standardised beta coefficients (95% CI) 
CK18  Model 1 p R
2  Model 2 p R2 
Hepatic steatosis  0.302 (0.23 to 0.37)) <0.001 0.090  0.292 (0.22 to 0.36) <0.001 0.101 
Triglyceridesa, mmol/L  0.148 (0.06 to 0.23) <0.001 0.023  0.152 (0.07 to 0.23) <0.001 0.050 
Waist circumference, cm  0.142 (0.07 to 0.21) <0.001 0.019  0.128 (0.06 to 0.20) 0.001 0.034 
Fasting glucose, mmol/L  0.098 (0.03 to 0.17) 0.006 0.010  0.090 (0.02 to 0.16) 0.011 0.028 
Body mass index, kg/m2  0.100 (0.03 to 0.17) 0.006 0.010  0.098 (0.02 to 0.17) 0.009 0.027 
Diet controlled  -0.085 (-0.16 to -0.02) 0.017 0.007  -0.091 (-0.16 to -0.02) 0.011 0.027 
HbA1c, % or mmol/mol  0.086 (0.02 to 0.16) 0.034 0.007  0.081 (0.01 to 0.15) 0.025 0.026 
Any OAHA use  0.079 (0.01 to 0.15) 0.029 0.006  0.085 (0.01 to 0.16) 0.018 0.026 
Total cholesterol, mmol/L  -0.055 (-0.14 to 0.03) NS 0.003  -0.062 (-0.15 to 0.02) NS 0.028 
Insulin therapy  0.030 (-0.04 to 0.10) NS 0.001  0.028 (-0.05 to 0.10) NS 0.019 
Duration of diabetesa, years  0.010 (-0.06 to 0.08) NS -  0.017 (-0.06 to 0.09) NS 0.019 
         
ELF  Model 1 p R
2  Model 2 p R2 
Body mass index, kg/m2  0.154 (0.07 to 0.24) <0.001 0.024  0.187 (0.10 to 0.27) <0.001 0.137 
Duration of diabetesa, years  0.149 (0.06 to 0.23) 0.001 0.022  0.124 (0.04 to 0.21) 0.003 0.120 
Insulin therapy  0.143 (0.06 to 0.23) 0.001 0.019  0.152 (0.07 to 0.24) <0.001 0.127 
Diet controlled  -0.110 (-0.20 to -0.02) 0.012 0.012  -0.116 (-0.20 to -0.03) 0.006 0.118 
Waist circumference, cm  0.097 (0.01 to 0.19) 0.032 0.009  0.155 (0.07 to 0.24) <0.001 0.126 
Any OAHA use  0.059 (-0.03 to 0.15) NS 0.003  0.064 (-0.20 to 0.15) NS 0.109 
HbA1c, % or mmol/mol  0.047  (-0.04 to 0.13) NS 0.002  0.070 (-0.01 to 0.16) NS 0.112 
Hepatic steatosis  -0.029 (-0.12 to 0.06) NS 0.001  0.014 (-0.07 to 0.10) NS 0.105 
Triglyceridesa, mmol/L  -0.025 (-0.13 to 0.08) NS 0.001  -0.001 (-0.10 to 0.10) NS 0.088 
Fasting glucose, mmol/L  0.018 (-0.07 to 0.11) NS -  0.030 (-0.05 to 0.11) NS 0.107 
Total cholesterol, mmol/L  -0.003 (-0.11 to 0.10) NS -  -0.042 (-0.15 to 0.06) NS 0.091 
a
 Analysed on the Log10 scale 
Model 1 - Unadjusted model, individual variables with no adjustment 
Model 2 - Individual variables adjusted for age, sex, alcohol excess, hepatotoxic medication use and strongly 
positive autoantibodies 
CK18, cytokeratin-18; ELF, European Liver Fibrosis panel; HbA1c, glycosylated haemoglobin; OAHA, oral 
anti-hyperglycaemic agent. 
